MSLN and cancer: Immunohistochemical studies confirmed the limited expression of MSLN in healthy tissues (mesothelial cells of the pleura, pericardium, peritoneum, fallopian tubes, and tonsils), underlining the potential to exploit it as target for cancer therapy [24].